MediciNova Announces That The National Institutes Of Health Neurological Disorders And Stroke Has Awarded $22M For An Intermediate Size Expanded Access Protocol To Evaluate The Efficacy Of MN-166 In Amyotrophic Lateral Sclerosis
Portfolio Pulse from Benzinga Newsdesk
MediciNova, Inc. (NASDAQ:MNOV) has announced a $22 million grant from the NIH to evaluate the efficacy of MN-166 in treating ALS through an Expanded Access Protocol. This trial will provide access to the drug for ALS patients not eligible for the COMBAT-ALS trial.
September 30, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MediciNova has been awarded a $22 million grant by the NIH to evaluate MN-166 for ALS treatment. This funding supports an Expanded Access Protocol, potentially increasing the drug's visibility and future market potential.
The NIH grant of $22 million is a significant endorsement of MN-166's potential in treating ALS, which could enhance MediciNova's reputation and future revenue prospects. The Expanded Access Protocol allows more patients to access the drug, increasing its exposure and potential market acceptance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100